固定剂量阿戈美拉汀短期治疗广泛性焦虑障碍的临床对照试验

发布时间：2018-02-09 12:16

本文关键词： 阿戈美拉汀丁螺环酮药物疗法焦虑症临床对照试验　出处：《中国新药与临床杂志》2015年07期 　论文类型：期刊论文

【摘要】：目的比较不同剂量组阿戈美拉汀治疗广泛性焦虑障碍的短期疗效和安全性。方法广泛性焦虑障碍患者86例随机分为阿戈美拉汀25 mg组(n=30)、50 mg组(n=28)和丁螺环酮组(n=28,30~45 mg·d-1),开放治疗6周。在治疗前及治疗后2、4、6周末采用汉密尔顿焦虑量表(HAMA)、临床疗效总评量表病情严重程度(CGI-SI)评定临床疗效,副反应量表(TESS)评定药物不良反应。结果三组治疗后HAMA总分和因子分、CGI-SI评分均显著下降(P0.05,P0.01)。阿戈美拉汀25 mg组有效率77%、临床治愈率33%,50 mg组有效率79%、临床治愈率54%,丁螺环酮组有效率75%、临床治愈率32%,三组有效率(χ2=0.100,P=0.951)、临床治愈率(χ2=3.430,P=0.180)比较无显著差异。HAMA、CGI评分显示阿戈美拉汀治疗2周起效(P0.05),且25 mg组与50 mg组比较无显著差异(P0.05)。TESS评分丁螺环酮组高于阿戈美拉汀两个剂量组(P0.01)。结论阿戈美拉汀25、50 mg·d-1短期治疗广泛性焦虑障碍均安全、有效。
[Abstract]:Objective to compare the short-term efficacy and safety of different doses of agomelatin in the treatment of generalized anxiety disorder. Methods 86 patients with generalized anxiety disorder were randomly divided into two groups: group A (n = 25) and group B (n = 50) and bupirone group (n = 45 mg 路d ~ (-1)). Open treatment for 6 weeks. Before and 2 weeks after treatment, Hamilton anxiety scale (Hamilton anxiety scale) was used to evaluate the clinical efficacy. Results after treatment, the total HAMA score and the factor score of CGI-SI were significantly decreased in the three groups. The effective rate of amelatin 25 mg group was 7710%, the clinical cure rate 33% 50 mg group was 79%, the clinical cure rate was 54%, and the clinical cure rate was 54%. The effective rate of cyclone group was 75 and the clinical cure rate was 320.There was no significant difference between the three groups (蠂 ~ (2 +) 0.100) and the clinical cure rate (蠂 ~ (2 +) 3.430 ~ 0.180). The CGI score of HAMAMA showed that the effective rate was P0.055.There was no significant difference between the 25 mg group and the 50 mg group in the score of buspira. Conclusion it is safe to treat general anxiety disorder with 2550 mg 路d -1 of Agonone in short term. Effective.
【作者单位】：新乡医学院第二附属医院临床心理科;
【基金】：河南省卫生科技创新型人才工程专项经费(编号4173)
【分类号】：R749.72

【共引文献】